CZ BioMed Corp. Announces 2.5 Year Survival of Stage 4 Colon Cancer Patient. Cancer Free After RVLYSIS
TAMPA, FL / ACCESSWIRE / November 11, 2015 / CZ BioMed Corp. announced today that on 11/11/2015 it has received positive results for patient, Mr. N Tran, diagnosed with advanced stage 4 colon cancer initially in February 2008 in Singapore. Studies of MRIs both before and after treatment, accurately demonstrate elimination of all tumors.
Case report:
Mr. N Tran is a 71 years old Vietnamese male from Ho Chi Minh City in otherwise healthy condition before his cancer diagnosis. The tumors initially were invading the right pelvic cavity and colon. Prior to treatment, a multiparametric MRI was performed. Mr. Tran then opted to attempt surgery for removal, followed by traditional chemotherapy. Both proved unsuccessful long term as the cancer reappeared and began to seriously affect Mr. Tran's health negatively.
An MRI as of June 2013, showed a 4 x 4.1cm sized mass in the right pelvic cavity. Mr. Tran opted for treatment overseas, via CZ Biomed affiliates clinic, and received 48 doses of CZ Biomed's novel oncolytic virotherapy, RVLYSIS(R). The CO-RVLYSIS(R) (colon cancer directed) treatment was administered systemically, via I.V. only.
Mr. Tran noted that no ill side effects were experienced from the CO-RVLYSIS(R) treatment and overall health appeared to begin to improve.
On March 25, 2014, a follow up scan was performed. The scans were analyzed and compared. Existence of the previous tumor was not found. There was an enlarged mesentery lymph node in the right pelvis area approximately 1.5cm in size. Mr. Tran's health continued to improve greatly.
An MRI was again performed, October 13, 2014. Nothing irregular was found in the abdomen and entire gastrointestinal tract.
Most recently, an MRI performed on August 3, 2015, confirmed zero abdominal cancer related abnormalities were found. To date, Mr. Tran has demonstrated a full recovery and is enjoying a healthy, active, cancer-free lifestyle once again.
These eliminations are no doubt as a result of the 48 doses systemic administration of CO-RVLYSIS(R), as it has been well documented that all previous attempts to eliminate the cancer using traditional methods were unsuccessful.
RVLYSIS(R) is a genetically modified oncolytic virus that selectively targets and destroys cancer cells, while leaving surrounding non-malignant cells uninfected. The destruction of these cancer cells occurs either through direct lytic rupture via multiple cycles of viral replication or the subsequent induction of apoptosis, also known as programmed cell death. Thus, RVLYSIS(R) is vastly safer to use and easier for the body to process, as compared to traditional chemo – or radio-therapies of tumors, allowing patients to enjoy a much higher quality of life during treatment. Human RSV is a respiratory tract-specific virus (similar to the "common cold" virus) that primarily infects children (under 1 year of age), but it does not cause disease in young and older adults. This trait alone may prove CZ BioMed's RSV-based treatments to be much more easily accepted by patients, as well as the global medical community, compared with some much more dangerous viruses currently being investigated for their oncolytic properties.
"The results published today speak for themselves. Mr. Tran's transformation has been amazing. Our patients recover faster, stronger and with a higher quality of life during and after treatment with RVLYSIS(R). This is only the beginning." ~ Calvin Cao, Chairman/CEO/President of CZ BioMed Corp.
As a result of this milestone, CZ BioMed Corp. will now continue discussions with all interested global bio-pharmaceutical leaders regarding partnership and licensing arrangements.
To view these results in detail, visit www.czbiomed.com.
About CZ BioMed Corp:
CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of CZ BioMed Corp. is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people’s lives, we accept only the highest ethical and quality standards, both from ourselves and others.
For further information about CZ BioMed Corp. please visit: www.czbiomed.com.
Forward Looking Statements
This report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.
FOR FURTHER INFORMATION
CONTACT: info@czbiomed.com
Phone: 813-600-4088
SOURCE: CZ BioMed Corp.
